Details of the Drug

General Information of Drug (ID: DMWOSKJ)

Drug Name

Zolpidem

Synonyms

zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

307.4

Logarithm of the Partition Coefficient (xlogp)

2.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly absorbed from the gastrointestinal tract []
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 121 mcg/L []
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.6 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability: 72% of drug becomes completely available to its intended biological destination(s) [3]
Clearance: The total clearance of drug is 0.24-0.27 mL/min/kg [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.5 hours []
Metabolism: The drug is metabolized via various hepatic cytochrome P450 (CYP) isoenzymes [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4669 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.08% [6]
Vd: The volume of distribution (Vd) of drug is 0.54-0.68 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 23 mg/mL [2]

Chemical Identifiers

Formula: C19H21N3O
IUPAC Name: N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
Canonical SMILES: CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C
InChI: InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
InChIKey: ZAFYATHCZYHLPB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5732
ChEBI ID: CHEBI:10125
CAS Number: 82626-48-0
DrugBank ID: DB00425
TTD ID: D0T1WN
INTEDE ID: DR1735
ACDINA ID: D00744

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Modulator	[7]
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Modulator (allosteric modulator)	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[13]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[14]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Zolpidem (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Zolpidem caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Zolpidem caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Zolpidem and Oliceridine.	Acute pain [MG31]	[17]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Zolpidem caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[16]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Zolpidem caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Zolpidem caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[19]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Zolpidem caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[20]
Ciprofloxacin XR	DM2NLS9	Major	Decreased metabolism of Zolpidem caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Zolpidem caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[21]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Zolpidem caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Zolpidem caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Zolpidem caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Zolpidem caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Zolpidem caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Zolpidem caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Zolpidem caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[16]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Zolpidem and Dihydrocodeine.	Chronic pain [MG30]	[25]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Zolpidem and Olopatadine.	Conjunctiva disorder [9A60]	[26]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Zolpidem and Propofol.	Corneal disease [9A76-9A78]	[27]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Zolpidem and Alfentanil.	Corneal disease [9A76-9A78]	[17]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Zolpidem and Remifentanil.	Corneal disease [9A76-9A78]	[17]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Zolpidem caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[19]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Zolpidem caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[20]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Zolpidem caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Zolpidem and Ethanol.	Cystitis [GC00]	[19]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Zolpidem caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[29]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Zolpidem caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[30]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Zolpidem caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Zolpidem and Esketamine.	Depression [6A70-6A7Z]	[19]
Primidone	DM0WX6I	Moderate	Increased metabolism of Zolpidem caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Zolpidem caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Zolpidem caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Zolpidem caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Zolpidem caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Zolpidem caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Zolpidem caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Zolpidem caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[16]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Zolpidem caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Zolpidem caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Zolpidem caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Zolpidem caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[20]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Zolpidem and Brimonidine.	Glaucoma [9C61]	[32]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Zolpidem caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[16]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Zolpidem caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[33]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Zolpidem caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Zolpidem caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Zolpidem caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Zolpidem caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Zolpidem caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Zolpidem caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Zolpidem caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Zolpidem caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Zolpidem caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Ritonavir	DMU764S	Minor	Decreased metabolism of Zolpidem caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Zolpidem caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[20]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Zolpidem caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[37]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Zolpidem caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[16]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Zolpidem caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[20]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Zolpidem caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[16]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Zolpidem caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[38]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Zolpidem caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Zolpidem caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[16]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Zolpidem caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Zolpidem caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[39]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Zolpidem caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Zolpidem caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Zolpidem caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Danazol	DML8KTN	Moderate	Decreased metabolism of Zolpidem caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[20]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Zolpidem and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[40]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Zolpidem and Lasmiditan.	Migraine [8A80]	[41]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Zolpidem caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[42]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Zolpidem and Flibanserin.	Mood disorder [6A60-6E23]	[43]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Zolpidem and Thalidomide.	Multiple myeloma [2A83]	[44]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Zolpidem caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[16]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Zolpidem caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[45]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Zolpidem caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Zolpidem caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[46]
Modafinil	DMYILBE	Moderate	Increased metabolism of Zolpidem caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[16]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Zolpidem caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[20]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Zolpidem and Levomethadyl Acetate.	Opioid use disorder [6C43]	[25]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Zolpidem and Apraclonidine.	Optic nerve disorder [9C40]	[32]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Zolpidem caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[20]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Zolpidem and Pentazocine.	Pain [MG30-MG3Z]	[17]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Zolpidem and Dextropropoxyphene.	Pain [MG30-MG3Z]	[47]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Zolpidem and Butorphanol.	Pain [MG30-MG3Z]	[17]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Zolpidem and Oxymorphone.	Pain [MG30-MG3Z]	[17]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Zolpidem and Levorphanol.	Pain [MG30-MG3Z]	[17]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Zolpidem and Dezocine.	Pain [MG30-MG3Z]	[17]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Zolpidem and Nalbuphine.	Pain [MG30-MG3Z]	[17]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Zolpidem and Buprenorphine.	Pain [MG30-MG3Z]	[48]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Zolpidem and Hydrocodone.	Pain [MG30-MG3Z]	[17]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Zolpidem and Meperidine.	Pain [MG30-MG3Z]	[17]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Zolpidem and Oxycodone.	Pain [MG30-MG3Z]	[17]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Zolpidem caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[49]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Zolpidem caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[50]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Zolpidem caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Zolpidem caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[16]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Zolpidem caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[16]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Zolpidem and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[51]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Zolpidem caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[16]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Zolpidem caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[16]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Zolpidem and Fentanyl.	Sensation disturbance [MB40]	[17]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Zolpidem and Sufentanil.	Sensation disturbance [MB40]	[17]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Zolpidem caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[20]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Zolpidem caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Zolpidem caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Moderate	Increased metabolism of Zolpidem caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
LEE011	DMMX75K	Moderate	Decreased metabolism of Zolpidem caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Zolpidem caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[52]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Zolpidem and Tizanidine.	Tonus and reflex abnormality [MB47]	[53]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Zolpidem and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[51]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Zolpidem and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[51]
-----------


⏷ Show the Full List of 112 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Saccharin sodium anhydrous	E00443	656582	Flavoring agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carbonic acid disodium salt	E00199	10340	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Magnesium tartrate	E00514	13014144	Other agent
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium bitartrate	E00551	23666342	Antioxidant; Buffering agent; Complexing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 43 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Zolpidem 1.75 mg tablet	1.75 mg	Sublingual Tablet	Oral
Zolpidem 3.5 mg tablet	3.5 mg	Sublingual Tablet	Oral
Zolpidem 5 mg tablet	5 mg	Oral Tablet	Oral
Zolpidem 10 mg tablet	10 mg	Sublingual Tablet	Oral
Zolpidem 5 mg tablet	5 mg	Sublingual Tablet	Oral
Zolpidem 10 mg tablet	10 mg	Oral Tablet	Oral
Zolpidem 12.5 mg tablet	12.5 mg	Extended Release Oral Tablet	Oral
Zolpidem 6.25 mg tablet	6.25 mg	Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4348).
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	LaCagnin LB, Lutsie P, Colby HD: Conversion of spironolactone to 7 alpha-thiomethylspironolactone by hepatic and renal microsomes. Biochem Pharmacol. 1987 Oct 15;36(20):3439-44.
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
9	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010 Sep;66(9):955.
10	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
11	The influences of CYP2C91/3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
12	Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
13	Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00849.
14	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166170041)
15	Principles of Clinical Pharmacology (Third Edition). 2012, Pages 417-436
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
18	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
19	Cerner Multum, Inc. "Australian Product Information.".
20	Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
21	Greenblatt DJ, vonMoltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, RothSchechter B, Shader RI "Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole." Clin Pharmacol Ther 64 (1998): 661-71. [PMID: 9871431]
22	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
23	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
24	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
25	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
26	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
27	Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
28	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
29	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
30	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
31	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
32	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
33	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
34	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
35	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
36	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
37	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
38	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
39	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
40	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
41	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
42	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
44	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
45	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
47	Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
48	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
49	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
50	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
51	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
52	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
53	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.